Picaridin

In addition to causing discomfort, mosquito bites may also spread a variety of infectious diseases such as malaria, dengue fever and Zika virus, which has always been a key concern in the field of global public health prevention and control. Picaridin is a broad-spectrum anthelmintic active pharmaceutical ingredient (API) and is currently an internationally recognized safe and efficient mosquito repellent active ingredient. Its mechanism of action is to block the recognition of human sweat and respiratory volatiles by insect olfactory receptors, so that mosquitoes cannot locate the host. This ingredient has a good repellent effect on a variety of arthropods such as mosquitoes, ticks, midges and fleas, and its skin irritation is much lower than that of the traditional mosquito repellent ingredient DEET, making it suitable for people of all age groups including adults, infants over 2 months old and pregnant women. In addition to common outdoor anti-bite scenarios, it is also widely used in infection prevention and control in epidemic areas.

Data show that the global market size of mosquito repellent products was close to USD 18 billion in 2023, with a compound annual growth rate maintained at around 6.5%. Among them, the market share of picaridin as a high-end mosquito repellent ingredient continues to rise, and the total global demand for picaridin APIs exceeded 2,300 tons in 2023. At present, the global API production capacity is mainly concentrated in China, Germany and India, and domestic enterprises account for more than 60% of the global production capacity by virtue of their cost and compliance advantages. In terms of the domestic market, as consumers' requirements for the safety of mosquito repellent products increase, the growth rate of picaridin-containing mosquito repellent products has exceeded 20% for three consecutive years, the demand for upstream APIs continues to rise, the competitive pattern is relatively scattered, and leading enterprises have not yet formed an absolute monopoly.

The original research enterprise of picaridin is Bayer AG, Germany, and the original research trade name is Bayrepel®. The core compound patent was first applied for in the European Union in 1998 and expired globally in 2018. The main dosage forms approved for the original research include external sprays, lotions and mosquito repellent wipes, with common specifications of 5%, 10% and 20% concentration preparations, and the original research preparations have been included in the FDA Reference Listed Drug Catalog. As of the search time point, there are more than 30 registration entries of picaridin APIs on the platform of the Center for Drug Evaluation (CDE) of China, most of which are in Class A status. Dozens of external picaridin-containing mosquito repellent preparations have been approved for marketing in China, covering the categories of "Xiao" brand name and "Yao" brand name. (Data as of June 2025, please refer to the official CDE website for the latest information)

In response to the demand for picaridin quality research and registration and declaration, CATO provides a full set of impurity reference standards for this API, covering all related substances, residual solvents and degradation impurities that may be generated during the synthesis process. Most products are in stock, and for in-stock products, orders placed before 16:00 will be shipped on the same day. All reference standards comply with the regulatory requirements of the Chinese Pharmacopoeia, FDA and other regulations, and can directly support impurity qualitative and quantitative research as well as consistency evaluation work.